Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmachem Gains Phase 2 Claims Agreement, Plus Patent For New Product

This article was originally published in The Tan Sheet

Executive Summary

Pharmachem Laboratories' experience with claims for its Phase 2 starch-neutralizer branded ingredient may provide an example for firms seeking to validate claims with the FDA, the firm says

You may also be interested in...



House Republicans Seek Top Down Change To FDA’s Warning-Letter Appeals

FDA leadership needs to review the agency's enforcement dispute resolution process, according to ranking Republicans on the House Energy and Commerce Committee

House Republicans Seek Top Down Change To FDA’s Warning-Letter Appeals

FDA leadership needs to review the agency's enforcement dispute resolution process, according to ranking Republicans on the House Energy and Commerce Committee

House Republicans Seek Top Down Change To FDA’s Warning-Letter Appeals

FDA leadership needs to review the agency's enforcement dispute resolution process, according to ranking Republicans on the House Energy and Commerce Committee

Related Content

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel